Skip to main content
SpringerLink
Log in

Can docetaxel plus estramustine prolong survival of men with metastatic hormone-refractory prostate cancer?

  • Practice Point
  • Published:

From Nature Clinical Practice Oncology

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Tannock IF et al. (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14: 1756–1764

    Article  CAS  Google Scholar 

  2. Kantoff PW et al. (1999) Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol 17: 2506–2513

    Article  CAS  Google Scholar 

  3. Berry W et al. (2002) Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol 168: 2439–2443

    Article  CAS  Google Scholar 

  4. Abratt RP et al. (2004) Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer. Ann Oncol 15: 1613–1621

    Article  CAS  Google Scholar 

  5. Tannock IF et al. (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502–1512

    Article  CAS  Google Scholar 

  6. National Institute of Health (NIH) (Online 17 December 2004) Clinical trials. (Accessed 6 November 2004)

Download references

Acknowledgements

The synopsis was written by Petra Roberts, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. staff member of the Department of Medical Oncology at the Erasmus University Medical Center, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands

    Stefan Sleijfer

  2. Chairman of the Department of Medical Oncology, Erasmus University Medical Center, Rotterdam, The Netherlands

    Gerrit Stoter

Authors
  1. Stefan Sleijfer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gerrit Stoter
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gerrit Stoter.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sleijfer, S., Stoter, G. Can docetaxel plus estramustine prolong survival of men with metastatic hormone-refractory prostate cancer?. Nat Rev Clin Oncol 2, 70–71 (2005). https://doi.org/10.1038/ncponc0076

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0076

  • Springer Nature Limited

Search

Navigation